Press Releases :: BiomX, Inc. (PHGE)

Dec 02, 2019 7:30am EST

BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin

Nov 12, 2019 7:30am EST

BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis

Nov 04, 2019 5:38pm EST

BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director

Nov 04, 2019 7:30am EST

BiomX To Present at Plenary Session of the AASLD Liver Conference

Oct 15, 2019 7:30am EDT

BiomX Appoints Merav Bassan as Chief Development Officer

Sep 30, 2019 7:30am EDT

BiomX Presents In Vivo Data on Bacteriophage Delivery to Intra-Tumor Bacteria

Sep 30, 2019 7:30am EDT

BiomX to Present at the Cantor Fitzgerald Global Healthcare Conference

Sep 09, 2019 8:00am EDT

BiomX Hosting Key Opinion Leader Symposium on Novel Phage Product for Acne Prone Skin

Aug 27, 2019 7:30am EDT

BiomX Announces In-house Phage Manufacturing Facility

Jun 11, 2019 2:00am EDT

BiomX Licenses Novel Targets for Liver Disease Phage Therapy Program From JSR Corporation in Japan

Previous
1…
1
2
3
4
5
6
7
8
9
10
Next

Investor Contact Information

Company

BiomX, Inc.
22 Einstein St.
Floor 5
Ness Ziona 7414003
Israel
info@biomx.com

Investor Relations

Anat Primovich
Corporate Project Manager
T: +972506977228
anatp@biomx.com